Alzheimer's disease consists of three distinct subtypes, according to study

September 16, 2015 by Kim Irwin
Diagram of the brain of a person with Alzheimer's Disease. Credit: Wikipedia/public domain.

Alzheimer's disease, long thought to be a single disease, really consists of three distinct subtypes, according to a UCLA study. The finding could lead to more highly targeted research and, eventually, new treatments for the debilitating neurological disorder, which robs people of their memories.

The study further found that one of the three variations, the cortical subtype, appears to be fundamentally a different condition than the other two, said Dr. Dale Bredesen, the study's author, a UCLA professor of neurology and member of the Easton Laboratory for Neurodegenerative Disease Research.

"Because the presentation varies from person to person, there has been suspicion for years that Alzheimer's represents more than one illness," said Bredesen, who also is the founding president of the Buck Institute for Research on Aging. "When go beyond the usual tests, we find these three distinct subtypes.

"The important implications of this are that the optimal treatment may be different for each group, there may be different causes, and, for future clinical trials, it may be helpful to study specific groups separately."

The subtypes are:

  • Inflammatory, in which markers such as C-reactive protein and serum albumin to globulin ratios are increased.
  • Non-inflammatory, in which these markers are not increased but other metabolic abnormalities are present.
  • Cortical, which affects relatively young individuals and appears more widely distributed across the brain than the other subtypes of Alzheimer's. It typically does not seem to cause memory loss at first, but people with this subtype of the disease tend to lose language skills. It is often misdiagnosed, typically affects people who do not have an Alzheimer's-related gene and is associated with a significant zinc deficiency.

The findings of the two-year study, which involved metabolic testing of 50 people, appear in the current issue of the peer-reviewed journal Aging.

No effective therapy for Alzheimer's exists. And scientists have yet to completely identify the cause, although multiple studies have pointed to such as insulin resistance, hormonal deficiencies and hyperhomocysteinemia, a condition characterized by an abnormally high level of an amino acid in the blood.

In a 2014 paper, Bredesen showed that making lifestyle, exercise and diet changes designed to improve the body's metabolism reversed cognitive decline in nine out of 10 patients with early Alzheimer's disease or its precursors.

The current finding grew out of an extensive evaluation of the data from last year's study, and it could eventually help scientists pinpoint more precise targets for treatments—the same approach that has led to major advances in treating other diseases.

For example, Bredesen explained, researchers have recently been able to develop precise treatments for cancer by sequencing tumor genomes and comparing them to the patients' genomes to better understand what drives the formation and growth of tumors.

"However, in Alzheimer's disease, there is no tumor to biopsy," Bredesen said. "So how do we get an idea about what is driving the process? The approach we took was to use the underlying metabolic mechanisms of the disease process to guide the establishment of an extensive set of laboratory tests, such as fasting insulin, copper-to-zinc ratio and dozens of others."

Going forward, Bredesen and his team will seek to determine whether the subtypes have different underlying causes, and whether they respond differently to potential treatments.

The need for a new approach to treat Alzheimer's is urgent. It is the most common age-related dementia, and the number of people with the disease in the U.S. is expected to increase to 15 million in 2050, from nearly 6 million today. The cost to treat people in the U.S. with Alzheimer's and other dementias is expected to be $226 billion in 2015 alone, and could reach $1.1 trillion in 2050.

Explore further: Naturally occurring protein fragment found in brain inhibits key enzyme implicated in Alzheimer's

More information: "Metabolic profiling distinguishes three subtypes of Alzheimer's disease." Aging, Vol 7, No 8, pp 595-600, Published: 08/31/15. www.impactaging.com/papers/v7/n8/full/100801.html

Related Stories

Naturally occurring protein fragment found in brain inhibits key enzyme implicated in Alzheimer's

July 29, 2015
For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the ...

Alzheimer's may affect the brain differently in African-Americans than European-Americans

July 15, 2015
Alzheimer's disease may cause different changes in the brain, or pathologies, in African-Americans than in white Americans of European descent, according to a study published in the July 15, 2015, online issue of the medical ...

Epilepsy drug could help treat Alzheimer's disease

May 6, 2015
University of British Columbia researchers say a new epilepsy drug holds promise as a treatment for Alzheimer's disease.

Major Alzheimer's risk factor linked to red wine target

October 21, 2013
The major genetic risk factor for Alzheimer's disease (AD), present in about two-thirds of people who develop the disease, is ApoE4, the cholesterol-carrying protein that about a quarter of us are born with. But one of the ...

Insulin resistance increases risk for Alzheimer's disease, study finds

July 27, 2015
The fact that obesity increases the risk of cardiovascular disease and some cancers is well known. But a new Iowa State University study adds to the growing evidence that memory loss should also be a top concern.

Report claims success treating Alzheimer's memory loss

October 6, 2014
(HealthDay)— A researcher is reporting success in a small study of reversing memory problems associated with early stage Alzheimer's disease by using a complex program of lifestyle changes, supplements and hormones.

Recommended for you

Is the Alzheimer's gene the ring leader or the sidekick?

September 15, 2017
The notorious genetic marker of Alzheimer's disease and other forms of dementia, ApoE4, may not be a lone wolf.

Potential noninvasive test for Alzheimer's disease

September 6, 2017
In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer's disease and distinguishing between different types of ...

Researchers unlock the molecular origins of Alzheimer's disease

September 6, 2017
A "twist of fate" that is minuscule even on the molecular level may cause the development of Alzheimer's disease, VCU researchers have found.

Is dementia declining among older Americans?

September 5, 2017
(HealthDay)—Here's some good news for America's seniors: The rates of Alzheimer's and other forms of dementia have dropped significantly over the last decade or so, a new study shows.

Which genetic marker is the ring leader in the onset of Alzheimer's disease?

September 4, 2017
The notorious genetic marker of Alzheimer's disease and other forms of dementia, ApoE4, may not be a lone wolf.

A decline in navigational skills could predict neurodegenerative disease

August 30, 2017
Changes in how humans map their surroundings and construct and follow directions as they age have been understudied compared to effects on memory and learning. However, age-related declines in navigational ability are independent ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.